ArticleMolecular biology reports2026
Can alterations in miR-21, miR-1, and miR-224 expression predict personalized medicine chemotherapy in non-small cell lung cancer?
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a leading cause of cancer-related mortality worldwide, necessitating continued efforts to identify reliable biomarkers for improved detection and treatment strategies. Cisplatin has been approved for the treatment of lung cancer; however, its therapeutic efficacy is limited by drug resistance. Accordingly, previous studies have investigated microRNAs as potential predictors of drug resistance. METHODS AND
resultsIn this study, we aimed to investigate the roles of microRNAs (miR-21, miR-1, and miR-224) in cisplatin resistance while minimizing potential confounding factors by focusing on EGFR- and PD-1/PD-L1-negative patients. Formalin-fixed paraffin-embedded (FFPE) samples were obtained from 30 patients with metastatic NSCLC. Only negative samples for EGFR mutations and PD-1/PD-L1 expression were included to reduce effects. Patients were divided into resistant and sensitive groups based on their response to cisplatin treatment. MicroRNAs were extracted, and their expression levels were quantified by qRT-PCR and normalized to U6 small RNA levels. The expression levels of miR-21 (P = 0.048, r = 0.38) and miR-224 (P = 0.017, r = 0.46) were higher in chemoresistant patients (P < 0.05), whereas the expression level of miR-1 (P = 0.035, r = 0.41) was higher in chemosensitive patients (P < 0.05).
conclusionThis study was conducted within the framework of personalized medicine. Our findings suggest that miR-21, miR-1, and miR-224 may serve as potential biomarkers for predicting cisplatin resistance in NSCLC patients.
Indexed as
Identifiers
42268452What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.